MindMed to Participate in H.C. Wainwright Global Investment Conference
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced its participation in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference, with its presentation accessible from 7:00 a.m. ET on September 12, 2022. As a clinical stage biopharmaceutical company, MindMed focuses on developing innovative treatments for brain health disorders. The company aims to enhance patient outcomes through its drug candidates targeting serotonin, dopamine, and acetylcholine systems. A replay of the presentation will be available in the 'News & Media' section of MindMed's website.
Details
News Market Reaction – MNMD
The recorded move for MNMD in the trading session of this news was -7.06%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Sept. 7, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it will participate virtually at the H.C. Wainwright 24th Annual Global Investment Conference, and its presentation will be available beginning at 7:00 a.m. ET on September 12, 2022.
For details or to register to attend please visit https://hcwevents.com/annualconference/. A replay of the webcast will be available in the "News & Media" section of MindMed's website.
MindMed is a clinical stage biopharmaceutical company developing novel products to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.
MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.
For Media: media@mindmed.co
For Investors: ir@mindmed.co
View original content to download multimedia:https://www.prnewswire.com/news-releases/mindmed-to-participate-in-hc-wainwright-global-investment-conference-301619002.html
SOURCE Mind Medicine (MindMed) Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.